03 March 2026
03 March 2026
If approved, mCOMBRIAX would become the first combination Covid-flu jab to gain regulatory approval anywhere across the globe.
Both Novo and obesity market rival Eli Lilly have outlaid significant funds to ensure future demand for oral weight loss drugs is met.
The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.
The combined cash balance at closing is projected to fund operations through 2030.
Yuviwel’s approval marks a more convenient option compared to BioMarin’s daily injection Voxzogo.
The CHMP’s recommendation is based on LIBERTY-CUPID data, including two Phase III and the CUPIDKids studies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
